CJC-1295 without DAC (Modified GRF 1-29)
Mod GRF 1-29 · CJC-1295 NO DAC · CJC no DAC
Short-acting GHRH analog (~30 min half-life) usually paired with a GHRP for pulsatile GH release.
Overview
CJC-1295 without DAC, also called modified GRF 1-29, is a short-acting synthetic analog of growth hormone-releasing hormone (GHRH). It is engineered with four amino acid substitutions that resist enzymatic degradation, and it works at GHRH receptors on the pituitary to stimulate growth hormone release in a pulsatile, physiologic pattern. Without the drug affinity complex (DAC) found in the longer-acting version, its half-life drops to roughly 30 minutes with around 60% subcutaneous bioavailability. That short residence time is why it is typically paired with a GHRP like ipamorelin or GHRP-2, since the two classes amplify GH release through different pathways. CJC-1295 without DAC reached early clinical study but is not an approved medication.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.0 days
- Bioavailability
- 60%
- Typical dose
- 0.1–0.5 mg
Related compounds
CJC-1295 with DAC
Long-acting GHRH analog with a drug-affinity complex that extends half-life to ~6–8 days; weekly dosing.
Sermorelin
Bioidentical GHRH fragment used diagnostically and off-label to stimulate endogenous growth hormone.
Tesamorelin
N-terminally stabilized GHRH analog approved to reduce excess visceral fat in HIV lipodystrophy.
Protocols featuring CJC-1295 without DAC (Modified GRF 1-29)
Comments
Loading comments…